1g(α)-amino-N-hydroxy-acetamide derivatives

Details 1g(α)-amino-N-hydroxy-acetamide derivatives 1g(α)-amino-N-hydroxy-acetamide derivatives

2006-09-26

2006-09-26

Saeed, Kamal A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Nitrogen containing other than solely as a nitrogen in an...

C564S080000, C564S084000

Reexamination Certificate

active

07112611

ABSTRACT:
The invention relates to α-amino-N-hydroxy-acetamide derivatives of formula (I), wherein R is di-lower alkyl amino, 1,2,3-triazol-2yl or 1,2,4-triazol-4-yl, m represents an integer from 1 up to and including 10, and n represents an integer from 0 up to and including 10, and salts thereof; to processes for their preparation, pharmaceutical compositions comprising said hydroxamic acid derivatives, the use of such hydroxamic acid derivatives as medicaments, and a method of treating conditions or diseases mediated by matrix-degrading metalloproteinases (MMP's) using said derivatives alone or in combination with one or more other therapeutic agents.

REFERENCES:
patent: 2513826 (1950-07-01), Sprung et al.
patent: 4806528 (1989-02-01), Hanreich
patent: 5338755 (1994-08-01), Wagnon et al.
patent: 5455258 (1995-10-01), MacPherson et al.
patent: 5500337 (1996-03-01), Benard et al.
patent: 5663431 (1997-09-01), Di Malta et al.
patent: 5932695 (1999-08-01), Floyd et al.
patent: 6150394 (2000-11-01), Watanabe et al.
patent: 308860 (1989-03-01), None
patent: 915086 (1999-05-01), None
patent: 0 950 656 (1999-10-01), None
patent: 11-236369 (1999-08-01), None
patent: 96 00214 (1996-01-01), None
patent: 9833768 (1998-08-01), None
patent: 99 06340 (1999-02-01), None
patent: 00 44709 (2000-08-01), None
patent: 00 44713 (2000-08-01), None
patent: WO 01/10827 (2001-02-01), None
US Appl. No. #10/048,932.
Casini, et al., “Sulfonamides and sulfonylated derivatives as anticancer agents,” 2002, Current Cancer Drug Targets, vol. 2, pp. 55-75, especially p. 58.
Tamura, et al. “Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-Sulfonylamino acid derivatives,” 1998, vol. 41, pp. 640-649, especially p. 640.
Connell, et al. “Patent focus on cancer chemotherapeutics. II Angiogenesis agents: Apr. 2000-Sep. 2000,” 2001, vol. 11(1), pp. 77-114, especially p. 84.
Scozzafava et al., “Protease Inhibitors: Synthesis of Potent Bacterial Collagenase and Matrix Metalloproteinase Inhibitors Incorporating N-4-nitrobenzylsulphonylglycine Hydroxamate Moieties”,J. Med. Chem., vol. 43, No. 9, pp. 1858-1865 (2000).
MacPherson et al., “Discovery of CGS 27023A, Non-Peptidic, Potent and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in Rabbits,” J. Med. Chem., vol. 40, pp. 2525-2532 (1997).
Tamura et al., “Highly Selective and Orally Active Inhibitors of Type IV Collagenase (MMP-9 and MMP-2): N-Sulfonylamino Acid Derivatives,” J. Med. Chem, vol. 41, No. 4, pp. 640-649 (1998).
Uhlenbroek et al., Investigations on Agricultural Fungicides: I. Trichloromethyl thiolsulphonates. Recl. Trav. Chim. PAYS-BAS, vol. 75, pp. 129-146 (1956).

Affiliated with

Also associated with

Rating

1g(α)-amino-N-hydroxy-acetamide derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 1g(α)-amino-N-hydroxy-acetamide derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1g(α)-amino-N-hydroxy-acetamide derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3571633